

# John F Thompson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3743986/publications.pdf>

Version: 2024-02-01

766  
papers

54,359  
citations

1799

103  
h-index

1857

209  
g-index

779  
all docs

779  
docs citations

779  
times ranked

31313  
citing authors

#	ARTICLE	IF	CITATIONS
1	Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma", Journal of the American Academy of Dermatology, 2023, 88, e25-e26.	1.2	3
2	Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. Clinical Oncology, 2023, 35, e85-e93.	1.4	1
3	Residual melanoma in wide local excision specimens after "complete" excision of primary cutaneous in situ and invasive melanomas. Pathology, 2022, 54, 71-78.	0.6	2
4	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1607-1616.	0.7	11
5	Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!. British Journal of Dermatology, 2022, 186, 205-206.	1.5	2
6	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
7	Do we need to rethink the diagnoses melanoma "in situ" and severely dysplastic naevus?. British Journal of Dermatology, 2022, 186, 1030-1032.	1.5	12
8	Multomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	16.8	64
9	Competing risks analysis with missing cause-of-failure"penalized likelihood estimation of cause-specific Cox models. Statistical Methods in Medical Research, 2022, , 096228022110702.	1.5	0
10	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (>15mm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	1.2	3
11	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3
12	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). European Journal of Surgical Oncology, 2022, 48, 1280-1287.	1.0	7
13	Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma. International Journal of Environmental Research and Public Health, 2022, 19, 2331.	2.6	1
14	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	2.8	3
15	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
16	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44
17	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology, 2022, 54, 533-540.	0.6	3
18	Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevus. American Journal of Surgical Pathology, 2022, 46, 1048-1059.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945.	1.5	4
20	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	4
21	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	0
22	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
23	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. <i>JAAD International</i> , 2022, , .	2.2	2
24	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 7019-7028.	1.5	3
25	Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. <i>Npj Digital Medicine</i> , 2022, 5, .	10.9	3
26	Treatment of primary Merkel cell carcinoma: Radiotherapy can be an effective, less morbid alternative to surgery. <i>European Journal of Surgical Oncology</i> , 2021, 47, 483-485.	1.0	9
27	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1145-1151.	1.0	5
28	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. <i>British Journal of Surgery</i> , 2021, 108, 550-553.	0.3	7
29	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. <i>European Journal of Cancer</i> , 2021, 142, 10-17.	2.8	16
30	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021, 62, 168-176.	0.7	3
31	Ultrasound Examination of the Lymphatic Drainage Area and Regional Lymph Nodes in Melanoma Patients with In-Transit Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 1625-1631.	1.5	7
32	ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 1632-1633.	1.5	2
33	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	4.2	16
34	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 166.	4.1	21
35	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1290-1298.	2.4	14
36	Treatment of in-transit melanoma metastases using intralesional PV-10. <i>Melanoma Research</i> , 2021, 31, 232-241.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383.	1.2	25
38	Organ transplantation and outcomes in patients with a past history of melanoma: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2021, 35, e14287.	1.6	2
39	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 1243-1252.	1.6	28
40	A multicentre study of naevus-associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. <i>British Journal of Dermatology</i> , 2021, 185, 101-109.	1.5	13
41	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-II). <i>Cancer</i> , 2021, 127, 2251-2261.	4.1	37
42	Predicting sentinel node positivity in patients with melanoma: external validation of a risk prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort*. <i>British Journal of Dermatology</i> , 2021, 185, 412-418.	1.5	14
43	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. <i>Trials</i> , 2021, 22, 324.	1.6	10
44	Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. <i>Advances in Therapy</i> , 2021, 38, 3506-3530.	2.9	9
45	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. <i>Pathology</i> , 2021, 53, 830-835.	0.6	7
46	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021, 34, 1999-2008.	5.5	16
47	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.7	7
48	In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6915-6917.	1.5	0
49	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	2.8	1
50	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	1.5	8
51	The worse survival outcomes reported for melanoma patients having sentinel node biopsy after lymphoscintigraphy the previous day do not appear to be due to overnight migration of <sup>99m</sup> Tc-nanocolloid tracer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2450-2453.	1.0	0
52	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	12.8	33
53	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1659093.	4.6	62
54	Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. <i>Dermatology</i> , 2020, 236, 111-116.	2.1	23

#	ARTICLE	IF	CITATIONS
55	Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 561-568.	1.5	6
56	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 35-42.	1.5	4
57	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 910-919.	1.2	10
58	Current management of patients with melanoma who are found to be sentinel nodeâ€positive. <i>ANZ Journal of Surgery</i> , 2020, 90, 491-496.	0.7	12
59	A risk prediction model for the development of subsequent primary melanoma in a populationâ€based cohort. <i>British Journal of Dermatology</i> , 2020, 182, 1148-1157.	1.5	28
60	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 357-367.	3.7	10
61	First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 272-276.	1.0	1
62	Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. <i>Annals of Surgical Oncology</i> , 2020, 27, 1970-1977.	1.5	3
63	The intriguing association between smoking and reduced melanoma risk. <i>British Journal of Dermatology</i> , 2020, 182, 1080-1080.	1.5	1
64	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	12.8	102
65	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	1.0	8
66	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	3.7	27
67	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. <i>BMJ Open</i> , 2020, 10, e037857.	1.9	4
68	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725.	4.1	14
69	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	4.1	59
70	Multiplex melanoma families are enriched for polygenic risk. <i>Human Molecular Genetics</i> , 2020, 29, 2976-2985.	2.9	9
71	Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. <i>Melanoma Research</i> , 2020, 30, 358-363.	1.2	14
72	Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 515e-516e.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	3.4	13
74	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	1.5	8
75	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. JCO Precision Oncology, 2020, 4, 990-991.	3.0	2
76	New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.	1.7	0
77	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	1.0	5
78	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	1.6	84
79	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
80	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10
81	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	1.9	6
82	Evaluation of Sex-Specific Incidence of Melanoma. JAMA Dermatology, 2020, 156, 553.	4.1	65
83	Evidence-Based Follow-Up Schedules After Primary Cancer Treatment. Annals of Surgical Oncology, 2020, 27, 4067-4069.	1.5	1
84	The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 2020, 33, 1369-1379.	5.5	13
85	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	13.2	30
86	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
87	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. Journal of Pathology: Clinical Research, 2020, 6, 195-206.	3.0	35
88	Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
89	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
90	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2020, , 867-894.		3

#	ARTICLE	IF	CITATIONS
91	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
92	Australian general practitionersâ€™ attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.8	3
93	GPsâ€™ involvement in diagnosing, treating, and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study. BJGP Open, 2020, 4, bjgpopen20X101028.	1.8	11
94	A History of Melanoma: From Hunter to Morton. , 2020, , 1457-1475.		0
95	Models for Predicting Melanoma Outcome. , 2020, , 299-314.		0
96	Treatment of Primary Melanomas. , 2020, , 573-594.		0
97	Axillary and Epitrochlear Lymph Node Dissection for Melanoma. , 2020, , 657-667.		0
98	Lymphoscintigraphy in Patients with Melanoma. , 2020, , 205-237.		0
99	Biopsy of the Sentinel Lymph Node. , 2020, , 239-270.		0
100	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
101	Diagnosis and management of cutaneous melanoma. Australian Journal of General Practice, 2020, 49, 733-739.	0.8	8
102	Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using Tc-labelled antimony sulphide colloid. British Journal of Surgery, 2020, 107, 1773-1779.	0.3	1
103	Desmoplastic Melanoma. , 2019, , 469-481.		0
104	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 2019, 20, 477.	1.6	4
105	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
106	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.3	5
107	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2019, , 1-28.		0
108	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155



#	ARTICLE	IF	CITATIONS
109	Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2855-2863.	1.5	11
110	Appropriate excision margins for cutaneous melanomas. <i>Lancet</i> , The, 2019, 394, 445-446.	13.7	1
111	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. <i>Journal of Surgical Oncology</i> , 2019, 120, 1462-1469.	1.7	6
112	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1107-1119.	3.1	11
113	New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. <i>ANZ Journal of Surgery</i> , 2019, 89, 1187-1189.	0.7	0
114	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. <i>Annals of Surgical Oncology</i> , 2019, 26, 4663-4672.	1.5	3
115	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3141.	1.6	78
116	A History of Melanoma: From Hunter to Morton. , 2019, , 1-19.		1
117	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	10.7	126
118	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019, 10, 2230.	12.8	21
119	Multidisciplinary care of cancer patients: a passing fad or here to stay?. <i>ANZ Journal of Surgery</i> , 2019, 89, 464-465.	0.7	3
120	Molecular Genomic Profiling of MelanocyticÂNevi. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768.	0.7	55
121	Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1706-1711.	1.0	5
122	Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. <i>European Journal of Cancer</i> , 2019, 112, 9-11.	2.8	6
123	Longâ€Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	1.5	35
124	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1860-1868.	1.5	29
125	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	1.2	77
126	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1314-1322.	6.3	35



#	ARTICLE	IF	CITATIONS
127	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	16.8	547
128	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 832-837.	1.0	4
129	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 3247-3258.	7.0	27
130	ASO Author Reflections: Subungual Melanomas of the Hand Present Diagnostic and Therapeutic Challenges. <i>Annals of Surgical Oncology</i> , 2019, 26, 1044-1045.	1.5	2
131	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. <i>JAMA Dermatology</i> , 2019, 155, 502.	4.1	0
132	Response to Comment on "Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Staging. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e104-e105.	4.2	9
133	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	3.7	14
134	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1442-1444.	3.7	4
135	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma". <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e21-e22.	1.2	1
136	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060.	5.1	54
137	RAB27A promotes melanoma cell invasion and metastasis via regulation of proinvasive exosomes. <i>International Journal of Cancer</i> , 2019, 144, 3070-3085.	5.1	72
138	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	2.9	16
139	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	1.5	28
140	Letter re: Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma: A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1121.	1.0	3
141	Isolated Limb Infusion and Isolated Limb Perfusion for Melanoma: Can the Outcomes of these Procedures be Compared?. <i>Annals of Surgical Oncology</i> , 2019, 26, 8-9.	1.5	8
142	Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia. <i>BMJ Quality and Safety</i> , 2019, 28, 253-254.	3.7	1
143	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. <i>Annals of Surgical Oncology</i> , 2019, 26, 25-32.	1.5	21
144	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Onc Immunology</i> , 2019, 8, e1537581.	4.6	61

#	ARTICLE	IF	CITATIONS
145	The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management. Australasian Journal of Dermatology, 2019, 60, 118-125.	0.7	21
146	Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. Medical Journal of Australia, 2019, 210, 41-47.	1.7	26
147	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. Annals of Surgical Oncology, 2019, 26, 315-317.	1.5	4
148	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 2019, 51, 39-45.	0.6	25
149	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. Australasian Journal of Dermatology, 2019, 60, 75-76.	0.7	1
150	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	1.8	31
151	Management of pigmented skin lesions in childhood and adolescence. Australian Journal of General Practice, 2019, 48, 539-544.	0.8	5
152	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian Journal of General Practice, 2019, 48, 357-362.	0.8	9
153	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
154	Treatment of Primary Melanomas. , 2019, , 1-22.		0
155	Biopsy of the Sentinel Lymph Node. , 2019, , 1-32.		0
156	Models for Predicting Melanoma Outcome. , 2019, , 1-16.		0
157	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0
158	Desmoplastic Melanoma. , 2019, , 1-13.		0
159	Melanoma Prognosis and Staging. , 2019, , 1-27.		0
160	Management of pigmented skin lesions during pregnancy. Australian Journal of General Practice, 2019, 48, 621-624.	0.8	5
161	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. Pathology, 2018, 50, 364-367.	0.6	3
162	More on Adjuvant Therapy in Resected Melanoma. New England Journal of Medicine, 2018, 378, 1656-1657.	27.0	5

#	ARTICLE	IF	CITATIONS
163	Impact of genomics on the surgical management of melanoma. British Journal of Surgery, 2018, 105, e31-e47.	0.3	3
164	Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Research, 2018, 28, 134-142.	1.2	20
165	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. American Journal of Surgical Pathology, 2018, 42, 359-366.	3.7	11
166	Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia. Annals of Surgical Oncology, 2018, 25, 617-625.	1.5	18
167	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. Annals of Surgical Oncology, 2018, 25, 894-902.	1.5	69
168	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	7.0	297
169	A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 2018, 12, 1700094.	1.6	0
170	Surgical Technique for Open Inguinal Lymphadenectomy. , 2018, , 185-195.		1
171	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. Annals of Surgical Oncology, 2018, 25, 918-919.	1.5	1
172	Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 2018, 9, 4627.	12.8	79
173	ASO Author Reflections: Limited Surgery Plus Radiotherapy for Melanoma Patients with Cervical Node Metastases. Annals of Surgical Oncology, 2018, 25, 912-913.	1.5	11
174	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. Journal of Surgical Oncology, 2018, 118, 599-605.	1.7	13
175	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 2018, 25, 2541-2549.	1.5	35
176	When is surgery for metastatic melanoma still the most appropriate treatment option?. Expert Review of Anticancer Therapy, 2018, 18, 943-945.	2.4	2
177	Continuing and new roles for surgery in the management of patients with stage IV melanoma. Melanoma Management, 2018, 5, MMT03.	0.5	4
178	Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience. Annals of Surgical Oncology, 2018, 25, 2178-2183.	1.5	14
179	The role of sentinel lymph node biopsy as a staging procedure in patients with melanoma – A critical appraisal. Australasian Journal of Dermatology, 2018, 59, 235-236.	0.7	2
180	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. Annals of Surgical Oncology, 2018, 25, 3476-3482.	1.5	6

#	ARTICLE	IF	CITATIONS
181	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. British Journal of Cancer, 2018, 119, 713-723.	6.4	9
182	Isolated Limb Infusion for Recurrent and Locally Metastatic Limb Melanoma. , 2018, , 451-465.		1
183	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	10.7	131
184	Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Medical Journal of Australia, 2018, 208, 137-142.	1.7	32
185	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	2.8	14
186	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. Journal of Clinical Oncology, 2018, 36, 9518-9518.	1.6	0
187	Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. Journal of the American College of Surgeons, 2017, 224, 635-642.	0.5	21
188	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2017, 24, 2089-2094.	1.5	22
189	Parallel multicentre randomised trial of a clinical trial question prompt list in patients considering participation in phase 3 cancer treatment trials. BMJ Open, 2017, 7, e012666.	1.9	7
190	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	3.7	40
191	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
192	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
193	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	27.0	1,087
194	Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Research, 2017, 27, 457-462.	1.2	15
195	Melanoma patient imaging in the era of effective systemic therapies. European Journal of Surgical Oncology, 2017, 43, 1517-1527.	1.0	14
196	Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.	0.5	0
197	Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients. European Journal of Surgical Oncology, 2017, 43, 2163-2169.	1.0	3
198	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000.	1.5	102

#	ARTICLE	IF	CITATIONS
199	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	329.8	1,662
200	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the "Australian guidelines for the management of cutaneous melanoma"™. <i>Australasian Journal of Dermatology</i> , 2017, 58, 274-277.	0.7	12
201	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	7.0	75
202	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. <i>Modern Pathology</i> , 2017, 30, 1538-1550.	5.5	33
203	Role of sentinel lymph node biopsy as a staging procedure in patients with melanoma: A critical appraisal. <i>Australasian Journal of Dermatology</i> , 2017, 58, 268-273.	0.7	2
204	Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. <i>Pathology</i> , 2017, 49, 539-542.	0.6	11
205	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 3245-3251.	1.5	16
206	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	5.5	150
207	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<1mm) Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 660-660.	1.5	1
208	Regarding complications following completion lymphadenectomy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2374-2375.	1.0	0
209	Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 225, 302-311.	0.5	20
210	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. <i>Annals of Surgical Oncology</i> , 2017, 24, 2080-2088.	1.5	31
211	Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications. <i>Annals of Surgical Oncology</i> , 2017, 24, 2071-2079.	1.5	9
212	Clinical Features Associated With Individuals at Higher Risk of Melanoma. <i>JAMA Dermatology</i> , 2017, 153, 23.	4.1	43
213	Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia. <i>Australasian Journal of Dermatology</i> , 2017, 58, 278-285.	0.7	12
214	Outcome of Melanoma Patients Who Did Not Proceed to Sentinel Node Biopsy After Preoperative Lymphoscintigraphy. <i>Annals of Surgical Oncology</i> , 2017, 24, 117-126.	1.5	11
215	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1721-1729.	1.6	40
216	Title is missing!. , 2017, , .		82

#	ARTICLE	IF	CITATIONS
217	Conditional survival estimates for cancer patients. Oncotarget, 2017, 8, 84639-84640.	1.8	7
218	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
219	Sentinel Lymph Node Biopsy: Evolution of the Technique Since the Original Description by Morton et al. in 1992. Critical Reviews in Oncogenesis, 2016, 21, 7-17.	0.4	4
220	Radioguided Sentinel Lymph Node Mapping and Biopsy in Cutaneous Melanoma. , 2016, , 151-163.		1
221	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.6	26
222	Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension, 2016, 67, 1263-1272.	2.7	89
223	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 2016, 23, 2658-2663.	1.5	17
224	Doctorsâ€™ recognition and management of melanoma patientsâ€™ risk: An Australian population-based study. Cancer Epidemiology, 2016, 45, 32-39.	1.9	1
225	Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer, 2016, 16, 372.	2.6	14
226	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1â€“2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology, 2016, 23, 1071-1081.	1.5	31
227	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Annals of Surgical Oncology, 2016, 23, 1096-1103.	1.5	43
228	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3915-3923.	7.0	91
229	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	5.5	43
230	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Caseâ€“Control Study. Annals of Surgical Oncology, 2016, 23, 1082-1089.	1.5	43
231	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. Journal of Investigative Dermatology, 2016, 136, 245-254.	0.7	82
232	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.. Journal of Clinical Oncology, 2016, 34, 9583-9583.	1.6	9
233	Isolated Limb Infusion. , 2016, , 375-390.		0
234	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.6	9

#	ARTICLE	IF	CITATIONS
235	A recurrent germline <i>BAP1</i> mutation and extension of the <i>BAP1</i> tumor predisposition spectrum to include basal cell carcinoma. <i>Clinical Genetics</i> , 2015, 88, 267-272.	2.0	81
236	BAP1-inactivated Spitzoid Naevi. <i>American Journal of Surgical Pathology</i> , 2015, 39, 722.	3.7	16
237	Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours. <i>Australasian Journal of Dermatology</i> , 2015, 56, 227-231.	0.7	1
238	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with <i>BRAF</i> or combined <i>BRAF</i> and MEK inhibitors. <i>Cancer</i> , 2015, 121, 3826-3835.	4.1	40
239	Imaging Sentinel Lymph Nodes. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 25-32.	2.0	23
240	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. <i>BMC Research Notes</i> , 2015, 8, 192.	1.4	15
241	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Åmm) Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 2972-2977.	1.5	13
242	How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1164-1171.	1.5	11
243	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.9	270
244	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
245	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. <i>European Journal of Surgical Oncology</i> , 2015, 41, 830-836.	1.0	19
246	Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. <i>International Journal of Cancer</i> , 2015, 136, 863-874.	5.1	67
247	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2135-2142.	1.5	126
248	The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 4067-4072.	1.5	14
249	Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1959-1966.	1.5	73
250	Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor. <i>Annals of Surgical Oncology</i> , 2015, 22, 1598-1603.	1.5	20
251	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1049-1060.	10.7	173
252	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680.	6.1	86



#	ARTICLE	IF	CITATIONS
253	Should patients with melanoma brain metastases receive adjuvant whole-brain radiotherapy?. <i>Lancet Oncology</i> , The, 2015, 16, e195-e196.	10.7	5
254	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-“Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	7.0	120
255	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	5.5	37
256	Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management. <i>British Journal of Dermatology</i> , 2015, 172, 571-573.	1.5	21
257	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 475-481.	1.5	131
258	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 245-253.	3.3	356
259	Cross-cultural development of a quality-of-life measure for patients with melanoma. <i>Melanoma Research</i> , 2015, 25, 47-58.	1.2	16
260	The History of Sentinel Lymph Node Biopsy. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 3-6.	2.0	45
261	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544.	5.5	76
262	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015, 47, 1194-1199.	21.4	221
263	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10995-11000.	7.1	146
264	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 254-266.	3.3	59
265	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20011-e20011.	1.6	0
266	Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). <i>BMC Cancer</i> , 2014, 14, 780.	2.6	36
267	Sentinel Lymph Node Biopsy for Melanoma: A Plea to Let the Data be Heard. <i>Annals of Surgical Oncology</i> , 2014, 21, 3362-3364.	1.5	4
268	Reply to M. Perier-Muzet et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3203-3204.	1.6	3
269	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. <i>Modern Pathology</i> , 2014, 27, 175-183.	5.5	78
270	MSLT-“response of clinical trial investigators. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 680-680.	27.6	4

#	ARTICLE	IF	CITATIONS
271	A novel hypoxia-associated subset of FN1highMITFlow melanoma cells: identification, characterization, and prognostic value. <i>Modern Pathology</i> , 2014, 27, 1088-1100.	5.5	20
272	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014, 27, 1193-1202.	5.5	18
273	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 599-609.	27.0	1,203
274	Sentinel-Node Biopsy in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 2148-2150.	27.0	11
275	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. <i>Nature Communications</i> , 2014, 5, 5694.	12.8	295
276	Isolated limb infusion: Technical aspects. <i>Journal of Surgical Oncology</i> , 2014, 109, 352-356.	1.7	23
277	Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review. <i>Journal of Surgical Oncology</i> , 2014, 109, 348-351.	1.7	52
278	<scp>S</scp>entinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in <scp>M</scp>erkel cell carcinoma: A pilot case series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 353-359.	1.8	7
279	Sentinel node biopsy is now part of routine staging in patients with clinically localized melanoma. <i>ANZ Journal of Surgery</i> , 2014, 84, 701-702.	0.7	3
280	Local and regional therapies for melanoma: Many arrows in the quiver. <i>Journal of Surgical Oncology</i> , 2014, 109, 295-295.	1.7	19
281	Inpatient Homogeneity of BRAFV600E Expression in Melanoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 377-382.	3.7	66
282	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. <i>Pathology</i> , 2014, 46, 193-198.	0.6	19
283	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. <i>Annals of Surgical Oncology</i> , 2014, 21, 4324-4329.	1.5	13
284	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1106-1116.	3.3	16
285	Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 407-421.	3.3	6
286	Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. <i>Annals of Surgical Oncology</i> , 2014, 21, 292-299.	1.5	28
287	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt435-djt435.	6.3	64
288	Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 1075-1081.	1.5	123

#	ARTICLE	IF	CITATIONS
289	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	7.0	447
290	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. <i>Methods in Molecular Biology</i> , 2014, 1102, 287-324.	0.9	78
291	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.8	69
292	Radiofrequency ablation in metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 366-369.	1.7	13
293	Cardiac Metastasis in Merkel Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e52-e53.	1.6	15
294	Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 308-313.	1.7	63
295	Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible. <i>BMC Research Notes</i> , 2014, 7, 412.	1.4	12
296	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	1.6	20
297	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. <i>Modern Pathology</i> , 2014, 27, 936-944.	5.5	46
298	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	6.4	93
299	The Role of Sentinel Lymph Node Biopsy in Patients with Merkel Cell Carcinoma: Uncertainty Prevails. <i>Annals of Surgical Oncology</i> , 2014, 21, 1517-1519.	1.5	12
300	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. <i>Annals of Surgical Oncology</i> , 2014, 21, 3108-3116.	1.5	33
301	Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. <i>Annals of Surgical Oncology</i> , 2014, 21, 2245-2251.	1.5	35
302	Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. <i>Annals of Surgical Oncology</i> , 2014, 21, 3985-3991.	1.5	35
303	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. <i>Human Molecular Genetics</i> , 2014, 23, 226-238.	2.9	96
304	Primary oesophageal melanoma - a case report. <i>World Journal of Surgical Oncology</i> , 2014, 12, 77.	1.9	5
305	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. <i>Neuro-Oncology</i> , 2014, 16, 1499-1509.	1.2	65
306	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 111-120.	2.8	127

#	ARTICLE	IF	CITATIONS
307	Lymphatic drainage patterns from primary cutaneous tumours of the forehead: Refining the recommendations for selective neck dissection. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2014, 67, 1038-1044.	1.0	7
308	17. Peritoneal epithelioid mesothelioma in a patient with metastatic melanoma - an association seen in BAP1 mutations. Pathology, 2014, 46, S112.	0.6	0
309	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (≥4 mm in Thickness). Annals of Surgery, 2014, 260, 1095-1102.	4.2	12
310	Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. Annals of Surgery, 2014, 260, 149-157.	4.2	36
311	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Patients. Annals of Surgery, 2014, 259, e86.	4.2	7
312	Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02.. Journal of Clinical Oncology, 2014, 32, 9027-9027.	1.6	8
313	A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 2014, 5, 2912-2917.	1.8	60
314	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	1.8	31
315	Specialized Cancer Procedures and Surgery. , 2014, , 201-218.		0
316	Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases. Annals of Surgical Oncology, 2013, 20, 3961-3968.	1.5	146
317	Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. Annals of Surgical Oncology, 2013, 20, 3969-3975.	1.5	20
318	Follow-up of early stage melanoma: Specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. Journal of Surgical Oncology, 2013, 107, 463-468.	1.7	29
319	Effects of <sc>BRAF</sc> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell and Melanoma Research, 2013, 26, 499-508.	3.3	37
320	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
321	The important role of radiation treatment in the management of Merkel cell carcinoma. British Journal of Dermatology, 2013, 169, 975-982.	1.5	28
322	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. European Journal of Surgical Oncology, 2013, 39, 1164-1165.	1.0	2
323	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. European Journal of Surgical Oncology, 2013, 39, 179-184.	1.0	22
324	Mitotic rate in melanoma should be recorded as the number of mitoses per mm2 (not per high power) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.8	7

#	ARTICLE	IF	CITATIONS
325	Patients' perspectives of long-term follow-up for localised cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2013, 39, 297-303.	1.0	35
326	Margins of excision and prognostic factors for cutaneous eyelid melanomas. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013, 66, 1066-1073.	1.0	42
327	The Unpredictability of Lymphatic Drainage from the Ear in Melanoma Patients, and Its Implications for Management. <i>Annals of Surgical Oncology</i> , 2013, 20, 1707-1713.	1.5	14
328	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. <i>British Journal of Cancer</i> , 2013, 108, 924-931.	6.4	55
329	Data Set for Pathology Reporting of Cutaneous Invasive Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1797-1814.	3.7	106
330	BAP1 expression in cutaneous melanoma: a pilot study. <i>Pathology</i> , 2013, 45, 606-609.	0.6	30
331	The FACT-Melanoma Quality-of-Life Instrument. <i>Melanoma Research</i> , 2013, 23, 61-69.	1.2	12
332	What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. <i>Melanoma Research</i> , 2013, 23, 167-174.	1.2	17
333	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. <i>Pathology</i> , 2013, 45, 55-61.	0.6	15
334	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25564.	4.6	6
335	Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 326-337.	3.3	33
336	Biospecimen banking: The pathway to personalized medicine for patients with cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 681-682.	1.7	10
337	Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. <i>Journal of Surgical Oncology</i> , 2013, 108, 129-135.	1.7	39
338	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. <i>Clinical Cancer Research</i> , 2013, 19, 4589-4598.	7.0	115
339	Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. <i>Expert Review of Dermatology</i> , 2013, 8, 195-214.	0.3	7
340	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 509-517.	0.7	156
341	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	3.7	289
342	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. <i>Annals of Surgery</i> , 2013, 258, 152-157.	4.2	56

#	ARTICLE	IF	CITATIONS
343	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e320-e325.	3.8	15
344	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTC 0.1.02/TROG 02.01).. Journal of Clinical Oncology, 2013, 31, 9001-9001.	1.6	8
345	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e320-e325.	3.8	7
346	Isolierte arterielle Infusion von Extremitäten. , 2013, , 313-325.		0
347	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2012, 30, 2678-2683.	1.6	691
348	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	7.0	589
349	SOX2 contributes to melanoma cell invasion. Laboratory Investigation, 2012, 92, 362-370.	3.7	85
350	Intratumoral Molecular Heterogeneity in a <i>BRAF</i>-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	4.1	78
351	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i>-Mutant Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 3242-3249.	7.0	405
352	Peritoneal melanosis associated with metastatic melanoma involving the omentum. Pathology, 2012, 44, 255-257.	0.6	15
353	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. Annals of Surgery, 2012, 255, 1165-1170.	4.2	62
354	Cellular blue naevus involving the urinary bladder. Pathology, 2012, 44, 664-668.	0.6	5
355	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. Annals of Surgery, 2012, 255, 357-362.	4.2	83
356	Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III Melanoma. Annals of Surgery, 2012, 255, 771-776.	4.2	45
357	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	4.2	103
358	Sentinel node biopsy for breast cancer: then and now. ANZ Journal of Surgery, 2012, 82, 481-483.	0.7	0
359	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, The, 2012, 13, 589-597.	10.7	253
360	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	28.9	688



#	ARTICLE	IF	CITATIONS
361	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555.	1.5	155
362	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3325-3334.	1.5	59
363	Is Melphalan Dose Adjustment According to Ideal Body Weight Useful in Isolated Limb Infusion for Melanoma?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3050-3056.	1.5	19
364	The Management of Cervical Lymph Nodes in Patients with Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3926-3932.	1.5	17
365	Evaluation of Incomplete Sentinel Node Biopsy Procedures and Sentinel Node Positivity Rates as Surgical Quality-Assurance Parameters in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3919-3925.	1.5	6
366	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3310-3312.	1.5	7
367	Surgeons'™ Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey. <i>Annals of Surgical Oncology</i> , 2012, 19, 4322-4329.	1.5	42
368	The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2012, 19, 3301-3303.	1.5	36
369	Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians'™ perspectives and models of care. <i>BMC Health Services Research</i> , 2012, 12, 468.	2.2	19
370	Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2226-2234.	0.7	50
371	Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. <i>Clinical Oncology</i> , 2012, 24, e131-e136.	1.4	39
372	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. <i>Cancer</i> , 2012, 118, 4519-4529.	4.1	29
373	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. <i>Histopathology</i> , 2012, 61, 889-898.	2.9	42
374	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. <i>Histopathology</i> , 2012, 61, 702-710.	2.9	29
375	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. <i>British Journal of Dermatology</i> , 2012, 166, 1319-1326.	1.5	8
376	Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 1774-1781.	1.5	39
377	Sentinel Lymph Nodes Containing Very Small (<0.1Âmm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. <i>Annals of Surgical Oncology</i> , 2012, 19, 1089-1099.	1.5	45
378	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1782-1789.	1.5	30



#	ARTICLE	IF	CITATIONS
379	Publication and Interpretation of Clinical Trial Results: The Need for Caution. <i>Annals of Surgical Oncology</i> , 2012, 19, 1745-1747.	1.5	6
380	Long-termÂcure after complete resection and adjuvant immunotherapy for distant melanoma metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8534-8534.	1.6	1
381	Melanoma - a management guide for GPs. <i>Australian Family Physician</i> , 2012, 41, 470-3.	0.5	6
382	Topical Diphencyprone Immunotherapy for a Large Primary Melanoma on an Elderly Leg. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 1.	6.7	6
383	Sentinel Lymph Node Biopsy for Melanoma: Critical Assessment at its Twentieth Anniversary. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 57-78.	1.5	21
384	Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 750-756.	1.0	21
385	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. <i>Molecular Oncology</i> , 2011, 5, 124-136.	4.6	135
386	Quality Assurance Parameters and Predictors of Outcome for Ilioinguinal and Inguinal Dissection in a Contemporary Melanoma Patient Population. <i>Annals of Surgical Oncology</i> , 2011, 18, 2521-2528.	1.5	46
387	Cancerâ€testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. <i>European Journal of Cancer</i> , 2011, 47, 460-469.	2.8	49
388	Optimum excision margins for melanoma. <i>Lancet, The</i> , 2011, 378, 1608-1610.	13.7	6
389	Lymph Node Ratio Provides Prognostic Information in Addition to American Joint Committee on Cancer N Stage in Patients With Melanoma, Even If Quality of Surgery Is Standardized. <i>Annals of Surgery</i> , 2011, 253, 109-115.	4.2	48
390	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. <i>Annals of Surgery</i> , 2011, 253, 1155-1164.	4.2	34
391	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. <i>Histopathology</i> , 2011, 58, 886-895.	2.9	19
392	Isolated Limb Perfusion and Isolated Limb Infusion for Malignant Lesions of the Extremities. <i>Current Problems in Surgery</i> , 2011, 48, 371-430.	1.1	19
393	Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 1877-1883.	1.5	29
394	Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 3292-3299.	1.5	24
395	The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1999-2004.	6.4	13
396	Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. <i>BMC Cancer</i> , 2011, 11, 142.	2.6	62

#	ARTICLE	IF	CITATIONS
397	Guidelines for lymphoscintigraphy and F18 FDG PET scans in Melanoma. Journal of Surgical Oncology, 2011, 104, 405-419.	1.7	25
398	Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. Journal of Surgical Oncology, 2011, 104, 379-385.	1.7	112
399	Ultrasound assessment of lymph nodes in the management of early-stage melanoma. Journal of Surgical Oncology, 2011, 104, 354-360.	1.7	18
400	Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. Journal of Surgical Oncology, 2011, 104, 397-404.	1.7	37
401	Local and intralesional therapy of in-transit melanoma metastases. Journal of Surgical Oncology, 2011, 104, 391-396.	1.7	77
402	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, 1239-1246.	1.6	942
403	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	1.6	0
404	Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. Journal of Clinical Oncology, 2011, 29, 2199-2205.	1.6	313
405	Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 2011, 29, 4641-4646.	1.6	75
406	Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. Journal of Clinical Oncology, 2011, 29, e237-e240.	1.6	148
407	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2011, 131, 1631-1638.	0.7	153
408	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	3.7	5
409	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	4.2	1
410	Diagnostic value of 8.5-T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Research, 2010, 20, 311-317.	1.2	7
411	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	1.5	68
412	In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma. Annals of Surgical Oncology, 2010, 17, 663-664.	1.5	4
413	Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database. Annals of Surgical Oncology, 2010, 17, 2006-2014.	1.5	106
414	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	1.5	9

#	ARTICLE	IF	CITATIONS
415	Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 3015-3020.	1.5	30
416	Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. <i>Annals of Surgical Oncology</i> , 2010, 17, 1995-2005.	1.5	34
417	Re-evaluation of a Scoring System to Predict Nonsentinel-Node Metastasis and Prognosis in Melanoma Patients. <i>Journal of the American College of Surgeons</i> , 2010, 211, 522-525.	0.5	12
418	Prognostic factors in cutaneous desmoplastic melanoma. <i>Cancer</i> , 2010, 116, 4130-4138.	4.1	109
419	Functional anatomy of the lymphatics draining the skin: a detailed statistical analysis. <i>Journal of Anatomy</i> , 2010, 216, 344-355.	1.5	33
420	Quality of histopathological reporting on melanoma and influence of use of a synoptic template. <i>Histopathology</i> , 2010, 56, 768-774.	2.9	41
421	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. <i>Melanoma Research</i> , 2010, 20, 203-211.	1.2	8
422	Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. <i>Journal of Clinical Oncology</i> , 2010, 28, 2452-2459.	1.6	374
423	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. <i>Journal of Clinical Oncology</i> , 2010, 28, 4441-4449.	1.6	111
424	Lymphoma occurring in patients with cutaneous melanoma. <i>Journal of Clinical Pathology</i> , 2010, 63, 777-781.	2.0	13
425	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. <i>Pathology</i> , 2010, 42, 287-289.	0.6	13
426	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. <i>Modern Pathology</i> , 2010, 23, 45-53.	5.5	68
427	Extended experience and modifications in the design and concepts of the keystone design island flap. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 1359-1363.	1.0	44
428	The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). <i>Annals of Surgical Oncology</i> , 2010, 17, 3324-3329.	1.5	177
429	Free flap reconstruction for melanoma of the head and neck: indications and outcomes. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 205-212.	1.0	13
430	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. <i>Lancet Oncology</i> , The, 2010, 11, 391-400.	10.7	20
431	Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1039-1045.	3.3	7
432	Histologically Ambiguous (â€œBorderlineâ€œ) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1770-1777.	2.5	47

#	ARTICLE	IF	CITATIONS
433	Radiation in the Management of Primary and Regional Merkel Cell Carcinoma. <i>Modular Medicine and Medicinal</i> , 2010, , 229-238.	0.4	0
434	Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5614-5619.	1.6	91
435	Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors. <i>International Journal of Surgical Pathology</i> , 2009, 17, 361-367.	0.8	40
436	Cytological features of melanoma in exfoliative fluid specimens. <i>Journal of Clinical Pathology</i> , 2009, 62, 638-643.	2.0	9
437	Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. <i>Journal of Clinical Pathology</i> , 2009, 62, 915-919.	2.0	41
438	Three-dimensional visualization of skin lymphatic drainage patterns of the head and neck. <i>Head and Neck</i> , 2009, 31, 1316-1325.	2.0	42
439	Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. <i>Cancer</i> , 2009, 115, 1932-1940.	4.1	55
440	Lymph node ratio in melanoma. <i>Cancer</i> , 2009, 115, 2384-2387.	4.1	26
441	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. <i>Cancer</i> , 2009, 115, 5026-5037.	4.1	75
442	So-called "malignant blue nevus". <i>Cancer</i> , 2009, 115, 2949-2955.	4.1	66
443	Isolated limb infusion: A review. <i>Journal of Surgical Oncology</i> , 2009, 100, 169-177.	1.7	42
444	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1713-1742.	6.4	159
445	Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. <i>Histopathology</i> , 2009, 54, 462-470.	2.9	91
446	Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1972-1982.	0.7	27
447	Functional RET G691S polymorphism in cutaneous malignant melanoma. <i>Oncogene</i> , 2009, 28, 3058-3068.	5.9	62
448	Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2009, 50, 266-271.	0.7	48
449	The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 929-940.	1.5	49
450	The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 571-577.	1.5	42

#	ARTICLE	IF	CITATIONS
451	Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 1184-1192.	1.5	52
452	Isolated Limb Infusion as Palliative Treatment for Advanced Limb Disease in Patients with AJCC Stage IV Melanoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 1193-1201.	1.5	21
453	Major Amputation for Irresectable Extremity Melanoma After Failure of Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2009, 16, 1543-1547.	1.5	15
454	In Reply: Cost-Effectiveness of Sentinel Node Biopsy for Melanoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 2962-2963.	1.5	1
455	Final Version of 2009 AJCC Melanoma Staging and Classification. <i>Journal of Clinical Oncology</i> , 2009, 27, 6199-6206.	1.6	4,126
456	Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. <i>European Journal of Surgical Oncology</i> , 2009, 35, 313-319.	1.0	87
457	Sentinel node biopsy and standard of care for melanoma. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 872-875.	1.2	132
458	Surgical excision margins for primary cutaneous melanoma. <i>The Cochrane Library</i> , 2009, , CD004835.	2.8	119
459	Elemental bio-imaging of melanoma in lymph node biopsies. <i>Analyst, The</i> , 2009, 134, 450-453.	3.5	51
460	Reconstruction after wide excision of primary cutaneous melanomas: part 1—the head and neck. <i>Lancet Oncology, The</i> , 2009, 10, 700-708.	10.7	21
461	Cutaneous melanoma in the era of molecular profiling. <i>Lancet, The</i> , 2009, 374, 362-365.	13.7	100
462	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2009, 249, 641-647.	4.2	45
463	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. <i>Annals of Surgery</i> , 2009, 249, 473-480.	4.2	61
464	Sentinel Node Status Prediction by Four Statistical Models. <i>Annals of Surgery</i> , 2009, 250, 964-969.	4.2	28
465	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1386-1395.	3.7	95
466	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. <i>Melanoma Research</i> , 2009, 19, 94-99.	1.2	53
467	Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma. <i>Annals of Surgery</i> , 2009, 249, 1008-1013.	4.2	26
468	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA9084-LBA9084.	1.6	9

#	ARTICLE	IF	CITATIONS
469	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA9084-LBA9084.	1.6	11
470	The advantage of using a synoptic pathology report format for cutaneous melanoma. <i>Histopathology</i> , 2008, 52, 130-138.	2.9	82
471	Desmoplastic neurotropic melanoma. <i>Cancer</i> , 2008, 113, 2770-2778.	4.1	131
472	Follow-up schedules after treatment for malignant melanoma. <i>British Journal of Surgery</i> , 2008, 95, 1401-1407.	0.3	78
473	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. <i>Annals of Surgical Oncology</i> , 2008, 15, 323-332.	1.5	28
474	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). <i>Annals of Surgical Oncology</i> , 2008, 15, 302-309.	1.5	116
475	The Complex Relationships Between Sentinel Node Positivity, Patient Age, and Primary Tumor Desmoplasia: Analysis of 2303 Melanoma Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2008, 15, 630-637.	1.5	47
476	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma-Mass Spectrometry. <i>Annals of Surgical Oncology</i> , 2008, 15, 934-940.	1.5	8
477	Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients with Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1476-1484.	1.5	89
478	Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2008, 15, 2749-2756.	1.5	48
479	Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients?. <i>Annals of Surgical Oncology</i> , 2008, 15, 3022-3027.	1.5	36
480	Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy. <i>Annals of Surgical Oncology</i> , 2008, 15, 1741-1749.	1.5	56
481	Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience. <i>Annals of Surgical Oncology</i> , 2008, 15, 3003-3013.	1.5	146
482	Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2509-2518.	1.5	95
483	The Value of Sentinel Node Biopsy in Patients with Primary Cutaneous Melanoma. <i>Dermatologic Surgery</i> , 2008, 34, 550-555.	0.8	8
484	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. <i>Histopathology</i> , 2008, 53, 345-345.	2.9	5
485	The detection and significance of melanoma micrometastases in sentinel nodes. <i>Surgical Oncology</i> , 2008, 17, 165-174.	1.6	48
486	Pharmacokinetics of Regional Therapy: Isolated Limb Infusion and Other Low Flow Techniques for Extremity Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 795-804.	1.5	10

#	ARTICLE	IF	CITATIONS
487	Detection of second primary cutaneous melanomas. <i>European Journal of Surgical Oncology</i> , 2008, 34, 587-592.	1.0	29
488	Pathologic examination of sentinel lymph nodes from melanoma patients. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 100-111.	1.5	102
489	p16INK4a Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors. <i>Neoplasia</i> , 2008, 10, 1231-1239.	5.3	39
490	Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases. <i>Dermatology</i> , 2008, 216, 361-362.	2.1	10
491	Sentinel Node Biopsy: Facts to Clear the Alleged Clouds—Reply. <i>Archives of Dermatology</i> , 2008, 144, 687.	1.4	10
492	The rationale for sentinel-node biopsy in primary melanoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 510-511.	4.3	51
493	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1-10.	1.6	5
494	Current status of isolated limb infusion with mild hyperthermia for melanoma. <i>International Journal of Hyperthermia</i> , 2008, 24, 219-225.	2.5	13
495	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. <i>Clinical Cancer Research</i> , 2008, 14, 638-645.	7.0	141
496	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 715-723.	0.7	24
497	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. <i>Future Oncology</i> , 2008, 4, 535-551.	2.4	20
498	Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. <i>Melanoma Research</i> , 2008, 18, 161-162.	1.2	3
499	Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1396-1403.	3.7	69
500	False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. <i>Annals of Surgery</i> , 2008, 247, 1003-1010.	4.2	67
501	Guidelines for imaging in cutaneous melanoma. <i>Nuclear Medicine Communications</i> , 2008, 29, 877-879.	1.1	7
502	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1106-1107.	3.7	11
503	Chemoablation of metastatic melanoma using intralesional Rose Bengal. <i>Melanoma Research</i> , 2008, 18, 405-411.	1.2	124
504	Imaging in cutaneous melanoma. <i>Nuclear Medicine Communications</i> , 2008, 29, 847-876.	1.1	60



#	ARTICLE	IF	CITATIONS
505	Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. Melanoma Research, 2008, 18, 365-366.	1.2	0
506	Defining Lower Limb Lymphedema After Inguinal or Ilio-Inguinal Dissection in Patients With Melanoma Using Classification and Regression Tree Analysis. Annals of Surgery, 2008, 248, 286-293.	4.2	59
507	Sentinel Lymph Node Biopsy in Cutaneous Melanoma. , 2008, , 92-110.		2
508	The utility of ultrasound in patients with melanoma. Expert Review of Anticancer Therapy, 2007, 7, 1633-1642.	2.4	28
509	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808.	1.2	17
510	An Integrated Tree-Based Classification Approach to Prognostic Grouping with Application to Localized Melanoma Patients. Journal of Biopharmaceutical Statistics, 2007, 17, 445-460.	0.8	12
511	Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biology and Therapy, 2007, 6, 846-852.	3.4	91
512	Case 2-2007. New England Journal of Medicine, 2007, 356, 285-292.	27.0	3
513	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clinical Cancer Research, 2007, 13, 3825-3830.	7.0	67
514	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.7	72
515	Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology, 2007, 39, 551-557.	0.6	41
516	Authors'™ Response to a Letter to the Editor Re: Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery, 2007, 245, 828-829.	4.2	23
517	Metastatic Occlusion of a Lymphatic Collecting Vessel in a Patient With Cutaneous Melanoma and Clinically Normal Lymph Nodes. Clinical Nuclear Medicine, 2007, 32, 312-313.	1.3	8
518	Subungual Melanoma. American Journal of Surgical Pathology, 2007, 31, 1902-1912.	3.7	157
519	Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma. Annals of Surgery, 2007, 245, 591-596.	4.2	85
520	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. Journal of the American Academy of Dermatology, 2007, 56, 889-890.	1.2	16
521	Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. Journal of the American Academy of Dermatology, 2007, 56, 869-871.	1.2	40
522	Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma. Lancet Oncology, The, 2007, 8, 806-812.	10.7	50

#	ARTICLE	IF	CITATIONS
523	Sentinel Node Mapping for Melanoma: Results of Trials and Current Applications. Surgical Oncology Clinics of North America, 2007, 16, 35-54.	1.5	49
524	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 2007, 20, 416-426.	5.5	169
525	ABDOMINAL RESECTIONAL SURGERY IN METASTATIC MELANOMA. ANZ Journal of Surgery, 2007, 77, 813-813.	0.7	0
526	Prognostic value of sentinel lymph node biopsy. British Journal of Dermatology, 2007, 157, 405-405.	1.5	2
527	The Reproducibility in Routine Clinical Practice of Sentinel Lymph Node Identification by Pre-operative Lymphoscintigraphy in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2007, 14, 899-905.	1.5	39
528	Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. Annals of Surgical Oncology, 2007, 14, 1943-1952.	1.5	101
529	Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines. Annals of Surgical Oncology, 2007, 14, 1924-1933.	1.5	126
530	Mapping Melanoma Lymphoscintigraphy Data onto a 3D Anatomically Based Model. Annals of Biomedical Engineering, 2007, 35, 1444-1457.	2.5	9
531	An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Journal of Clinical Oncology, 2007, 25, 8508-8508.	1.6	119
532	Primary invasive melanoma on the head and neck: Distribution, ultraviolet exposure and histological subtype in 1,298 Australian patients. Journal of Clinical Oncology, 2007, 25, 8541-8541.	1.6	0
533	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. Journal of Clinical Oncology, 2007, 25, 8509-8509.	1.6	0
534	The Role of Lymphoscintigraphy in the Detection of Lymph Node Drainage in Melanoma. Surgical Oncology Clinics of North America, 2006, 15, 285-300.	1.5	28
535	Surgical Management of Primary Cutaneous Melanoma: Excision Margins and the Role of Sentinel Lymph Node Examination. Surgical Oncology Clinics of North America, 2006, 15, 301-318.	1.5	26
536	Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. European Journal of Surgical Oncology, 2006, 32, 780-784.	1.0	29
537	Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor—related apoptosis-inducing ligand. Human Pathology, 2006, 37, 1286-1294.	2.0	71
538	Primary Melanoma of the Lung. , 2006, , 293-297.		9
539	The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. Journal of Cutaneous Pathology, 2006, 33, 395-396.	1.3	22
540	BENEFITS OF SENTINEL NODE BIOPSY FOR MELANOMA: A REVIEW BASED ON INTERIM RESULTS OF THE FIRST MULTICENTER SELECTIVE LYMPHADENECTOMY TRIAL. ANZ Journal of Surgery, 2006, 76, 100-103.	0.7	18

#	ARTICLE	IF	CITATIONS
541	SURGICAL PROCEDURES FOR MELANOMA IN PUBLIC AND PRIVATE NEW SOUTH WALES HOSPITALS, 2001-2002. ANZ Journal of Surgery, 2006, 76, 318-324.	0.7	5
542	Re: Sydney Melanoma Unit patients and Multicenter Selective Lymphadenectomy Trial protocol. ANZ Journal of Surgery, 2006, 76, 1039-1040.	0.7	1
543	Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study. Annals of Surgical Oncology, 2006, 13, 809-816.	1.5	161
544	Is Sentinel Lymph Node Biopsy Appropriate in Patients With Thin Melanomas: Too Early To Tell?. Annals of Surgical Oncology, 2006, 13, 279-281.	1.5	18
545	Treatment of Refractory Chromomycosis by Isolated Limb Infusion with Melphalan and Actinomycin D. Journal of Cutaneous Medicine and Surgery, 2006, 10, 48-51.	1.2	20
546	Sentinel-Node Biopsy or Nodal Observation in Melanoma. New England Journal of Medicine, 2006, 355, 1307-1317.	27.0	1,679
547	The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology, 2006, 38, 287-301.	0.6	109
548	Survival in Patients With Desmoplastic Melanoma. Journal of Clinical Oncology, 2006, 24, e12-e12.	1.6	20
549	Lymphatic Drainage in Patients with Primary Cutaneous Melanoma - the Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy. Current Medical Imaging, 2006, 2, 261-270.	0.8	1
550	Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Review of Anticancer Therapy, 2006, 6, 671-678.	2.4	46
551	Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery, 2005, 242, 302-313.	4.2	632
552	Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research, 2005, 15, 45-51.	1.2	116
553	Histopathologic Excision Margin Affects Local Recurrence Rate. Annals of Surgery, 2005, 241, 326-333.	4.2	57
554	Minimally Invasive Radio-Guided Surgery for Recurrent Thyroid Cancer Using Iodine-123. Clinical Nuclear Medicine, 2005, 30, 43-44.	1.3	8
555	Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. Melanoma Research, 2005, 15, 531-537.	1.2	44
556	Melanoma Metastases in Regional Lymph Nodes Are Accurately Detected by Proton Magnetic Resonance Spectroscopy of Fine-Needle Aspirate Biopsy Samples. Annals of Surgical Oncology, 2005, 12, 943-949.	1.5	20
557	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 597-608.	1.5	67
558	Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as ?Pure? or ?Mixed? May Have Important Prognostic Significance. Annals of Surgical Oncology, 2005, 12, 197-199.	1.5	49

#	ARTICLE	IF	CITATIONS
559	Internal mammary node metastasis from primary cutaneous melanoma on the anterior chest. ANZ Journal of Surgery, 2005, 75, 723-725.	0.7	7
560	Who should treat patients with primary melanoma?. British Journal of Dermatology, 2005, 153, 459-460.	1.5	0
561	Intraoperative Frozen-Section Evaluation Can Reduce Accuracy of Pathologic Assessment of Sentinel Nodes in Melanoma Patients. Journal of the American College of Surgeons, 2005, 201, 821-823.	0.5	32
562	Music in the operating theatre. British Journal of Surgery, 2005, 82, 1586-1587.	0.3	21
563	Melanoma of the nose. British Journal of Surgery, 2005, 84, 986-989.	0.3	15
564	Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 18-23.	1.5	99
565	Selective Sentinel Lymphadenectomy: Progress to Date and Prospects for the Future. Cancer Treatment and Research, 2005, 127, 269-287.	0.5	17
566	Role of Lymphoscintigraphy for Selective Sentinel Lymphadenectomy. Cancer Treatment and Research, 2005, 127, 15-38.	0.5	33
567	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 2005, 58, 1163-1169.	2.0	74
568	Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biology and Therapy, 2005, 4, 1318-1324.	3.4	105
569	Cutaneous melanoma. Lancet, The, 2005, 365, 687-701.	13.7	511
570	Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncology, The, 2005, 6, 877-885.	10.7	69
571	The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes. Journal of Clinical Oncology, 2005, 23, 4588-4590.	1.6	114
572	Interleukin-10 regulates arterial pressure in early primate pregnancy. Cytokine, 2005, 29, 176-185.	3.2	38
573	In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. European Journal of Radiology, 2005, 53, 506-513.	2.6	25
574	Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. European Journal of Surgical Oncology, 2005, 31, 323-324.	1.0	8
575	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. Annals of Surgical Oncology, 2005, 12, 429-439.	1.5	109
576	Determinants of Outcome in Melanoma Patients With Cerebral Metastases. Journal of Clinical Oncology, 2004, 22, 1293-1300.	1.6	389

#	ARTICLE	IF	CITATIONS
577	Targeted alpha therapy for cancer. <i>Physics in Medicine and Biology</i> , 2004, 49, 3703-3712.	3.0	62
578	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. <i>American Journal of Clinical Pathology</i> , 2004, 122, 532-539.	0.7	117
579	Validity of reported melanoma incidence rates in New Zealand. <i>ANZ Journal of Surgery</i> , 2004, 74, 1016-1017.	0.7	1
580	Antimony concentrations in nodal tissue can confirm sentinel node identity. <i>Modern Pathology</i> , 2004, 17, 1191-1197.	5.5	17
581	Teaching points on lymphatic mapping for melanoma from the sydney melanoma unit. <i>Seminars in Oncology</i> , 2004, 31, 349-356.	2.2	21
582	Nuclear medicine aspects of melanoma and breast lymphatic mapping. <i>Seminars in Oncology</i> , 2004, 31, 338-348.	2.2	31
583	An Evidence-based Staging System for Cutaneous Melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 131-149.	329.8	322
584	Should Tumor Mitotic Rate and Patient Age, As Well As Tumor Thickness, be Used to Select Melanoma Patients for Sentinel Node Biopsy?. <i>Annals of Surgical Oncology</i> , 2004, 11, 233-235.	1.5	45
585	Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?. <i>Annals of Surgical Oncology</i> , 2004, 11, 119-121.	1.5	6
586	Sentinel node biopsy for melanoma: Where have we been and where are we going?. <i>Annals of Surgical Oncology</i> , 2004, 11, 147S-151S.	1.5	19
587	Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. <i>Annals of Surgical Oncology</i> , 2004, 11, 174S-178S.	1.5	13
588	Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision. <i>Cancer</i> , 2004, 101, 2141-2142.	4.1	20
589	The history and future of melanoma staging. <i>Journal of Surgical Oncology</i> , 2004, 86, 224-235.	1.7	18
590	Pathology of melanocytic lesions: New, controversial, and clinically important issues. <i>Journal of Surgical Oncology</i> , 2004, 86, 200-211.	1.7	54
591	Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. <i>Journal of Surgical Oncology</i> , 2004, 88, 1-3.	1.7	48
592	Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 829-836.	1.5	71
593	The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up. <i>Annals of Surgical Oncology</i> , 2004, 11, 426-433.	1.5	180
594	Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. <i>European Journal of Surgical Oncology</i> , 2004, 30, 433-439.	1.0	35

#	ARTICLE	IF	CITATIONS
595	Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. <i>European Journal of Surgical Oncology</i> , 2004, 30, 1107-1112.	1.0	45
596	Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. <i>Pathology</i> , 2004, 36, 561-565.	0.6	18
597	Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. <i>Annals of Surgery</i> , 2004, 239, 544-552.	4.2	106
598	Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. <i>Melanoma Research</i> , 2004, 14, 263-268.	1.2	21
599	Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. <i>Pathology</i> , 2004, 36, 419-427.	0.6	71
600	Spitz naevus: diagnostic problems and their management implications. <i>Pathology</i> , 2004, 36, 452-457.	0.6	47
601	Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. <i>Pathology</i> , 2004, 36, 496-503.	0.6	34
602	Sentinel Node Biopsy for Melanoma: Where Have We Been and Where Are We Going?. <i>Annals of Surgical Oncology</i> , 2004, 11, 147S-151S.	1.5	43
603	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. <i>American Journal of Clinical Pathology</i> , 2004, 122, 532-539.	0.7	23
604	Surgical treatment of splenic metastases in patients with melanoma. <i>Journal of the American College of Surgeons</i> , 2003, 197, 38-43.	0.5	49
605	Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. <i>Cancer</i> , 2003, 97, 1488-1498.	4.1	372
606	Prognosis for patients with thin cutaneous melanoma. <i>Cancer</i> , 2003, 98, 1223-1231.	4.1	121
607	New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. <i>Journal of Surgical Oncology</i> , 2003, 21, 43-52.	1.4	103
608	The Sydney Melanoma Unit—a multidisciplinary melanoma treatment center. <i>Surgical Clinics of North America</i> , 2003, 83, 431-451.	1.5	12
609	Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. <i>Analyst</i> , 2003, 128, 217-219.	3.5	18
610	Psychological responses of patients receiving a diagnosis of cancer. <i>Annals of Oncology</i> , 2003, 14, 48-56.	1.2	347
611	Increased expression of apoptotic markers in melanoma. <i>Melanoma Research</i> , 2003, 13, 137-145.	1.2	47
612	Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions. <i>Melanoma Research</i> , 2003, 13, 581-586.	1.2	16

#	ARTICLE	IF	CITATIONS
613	Asking questions can help: development of a question prompt list for cancer patients seeing a surgeon. <i>European Journal of Cancer Prevention</i> , 2003, 12, 397-405.	1.3	50
614	Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1571-1576.	3.7	147
615	Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. <i>Melanoma Research</i> , 2003, 13, 259-261.	1.2	27
616	Argyrophilic Staining of Nucleolar Organizer Region Count and Morphometry in Benign and Malignant Melanocytic Lesions. <i>American Journal of Dermatopathology</i> , 2003, 25, 190-197.	0.6	27
617	Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1197-1202.	3.7	102
618	Hepatic surgery for metastatic melanoma. , 2003, , 505-513.		0
619	Melanoma of the urogenital tract. , 2003, , 636-640.		0
620	Primary pulmonary melanoma. , 2003, , 641-647.		1
621	Patterns of lymphatic drainage from the skin in patients with melanoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 570-82.	5.0	128
622	Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. <i>Journal of Neurosurgery</i> , 2002, 96, 552-558.	1.6	78
623	Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 4181-4190.	1.6	144
624	Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. <i>Cancer</i> , 2002, 94, 283-284.	4.1	1
625	Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. <i>Annals of Surgical Oncology</i> , 2002, 9, 127-136.	1.5	118
626	The Prognosis of Patients With Thick Primary Melanomas: Is Regional Lymph Node Status Relevant, and Does Removing Positive Regional Nodes Influence Outcome?. <i>Annals of Surgical Oncology</i> , 2002, 9, 719-722.	1.5	5
627	Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. <i>British Journal of Cancer</i> , 2001, 85, 157-165.	6.4	39
628	Lymph-node metastases in patients with melanoma: what is the optimum management?. <i>Lancet Oncology</i> , The, 2001, 2, 614-621.	10.7	23
629	Anomalous Lymphatic Drainage Patterns in Patients with Cutaneous Melanoma. <i>Tumori</i> , 2001, 87, 54-56.	1.1	6
630	Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. <i>Melanoma Research</i> , 2001, 11, 611-618.	1.2	27



#	ARTICLE	IF	CITATIONS
631	Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. <i>Melanoma Research</i> , 2001, 11, 423-431.	1.2	29
632	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	1.6	2,394
633	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 3635-3648.	1.6	2,462
634	Hearing the bad news of a cancer diagnosis: The Australian melanoma patient's perspective. <i>Annals of Oncology</i> , 2001, 12, 365-371.	1.2	100
635	Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role. <i>Annals of Surgical Oncology</i> , 2001, 8, 564-565.	1.5	42
636	Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2001, 8, 766-770.	1.5	109
637	Sentinel lymph node biopsy in patients with melanoma and breast cancer. <i>Internal Medicine Journal</i> , 2001, 31, 547-553.	0.8	18
638	CASE REPORT Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. <i>Australasian Journal of Dermatology</i> , 2001, 42, 106-109.	0.7	18
639	Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern?. <i>Head and Neck</i> , 2001, 23, 785-790.	2.0	90
640	Surgical Resection for Metastatic Melanoma to the Liver. <i>Archives of Surgery</i> , 2001, 136, 950.	2.2	142
641	Lymphatic mapping and sentinel node biopsy for melanoma. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 446-452.	2.4	8
642	Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2001, 8, 766-770.	1.5	5
643	Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role. <i>Annals of Surgical Oncology</i> , 2001, 8, 564-565.	1.5	2
644	The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. <i>Annals of Surgical Oncology</i> , 2001, 8, 44S-47S.	1.5	29
645	Anomalous lymphatic drainage patterns in patients with cutaneous melanoma. <i>Tumori</i> , 2001, 87, S54-6.	1.1	0
646	Interval Nodes. <i>Archives of Surgery</i> , 2000, 135, 1168.	2.2	154
647	Locally advanced melanoma. <i>Cancer</i> , 2000, 88, 88-94.	4.1	120
648	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , 2000, 88, 1484-1491.	4.1	389

#	ARTICLE	IF	CITATIONS
649	Sentinel Node Metastasis From Thin Melanomas With Vertical Growth Phase. Annals of Surgical Oncology, 2000, 7, 251-252.	1.5	19
650	Letter to the Editor. Annals of Surgical Oncology, 2000, 7, 790-790.	1.5	2
651	EDITORIAL "What is a "sentinel" lymph node?. European Journal of Surgical Oncology, 2000, 26, 103-104.	1.0	35
652	Popliteal lymph node metastasis from primary cutaneous melanoma. European Journal of Surgical Oncology, 2000, 26, 172-176.	1.0	76
653	Locally advanced melanoma. , 2000, 88, 88.		1
654	Regarding Pedunculated Malignant Melanoma. Dermatologic Surgery, 2000, 26, 812.	0.8	1
655	Regarding Amelanotic Melanomas. Dermatologic Surgery, 1999, 25, 918.	0.8	1
656	High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Journal of Medical Imaging and Radiation Oncology, 1999, 43, 148-152.	0.6	24
657	PRIMARY MUCOSAL AND GLANS PENIS MELANOMAS: THE SYDNEY MELANOMA UNIT EXPERIENCE. Australian and New Zealand Journal of Surgery, 1999, 69, 121-126.	0.2	36
658	Melanoma Metastases in Triangular Intermuscular Space Lymph Nodes. Annals of Surgical Oncology, 1999, 6, 811-811.	1.5	13
659	Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy11No competing interests declared.. Journal of the American College of Surgeons, 1999, 189, 195-204.	0.5	202
660	Superior survival of young women with malignant melanoma. American Journal of Surgery, 1999, 178, 358.	1.8	1
661	Surgical Management of Conjunctival Melanomas. JAMA Ophthalmology, 1999, 117, 1098.	2.4	4
662	Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma. Annals of Surgery, 1999, 230, 453.	4.2	694
663	Direct Lymphatic Drainage From a Melanoma on the Back to Paravertebral Lymph Nodes in the Thorax. Clinical Nuclear Medicine, 1999, 24, 388-389.	1.3	10
664	CADAVERIC LIVER PROCUREMENT USING AORTIC PERFUSION ONLY. ANZ Journal of Surgery, 1998, 68, 275-277.	0.7	23
665	TREATMENT OF LARGE, PERSISTENT LYMPHOCOELES USING AN ARGON BEAM COAGULATOR AND TALC. ANZ Journal of Surgery, 1998, 68, 743-744.	0.7	11
666	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. , 1998, 82, 1799-1800.		4

#	ARTICLE	IF	CITATIONS
667	Desmoplastic and desmoplastic neurotropic melanoma. Cancer, 1998, 83, 1128-1135.	4.1	295
668	Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Journal of Surgical Oncology, 1998, 14, 238-247.	1.4	194
669	Lymphatic drainage from the skin of the back to retroperitoneal and paravertebral lymph nodes in melanoma patients. Annals of Surgical Oncology, 1998, 5, 384-387.	1.5	52
670	Demonstration of second-tier lymph nodes during preoperative lymphoscintigraphy for melanoma: Incidence varies with primary tumor site. Annals of Surgical Oncology, 1998, 5, 517-521.	1.5	28
671	Epitrochlear lymph nodes as a site of melanoma metastasis. Annals of Surgical Oncology, 1998, 5, 248-252.	1.5	47
672	Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas ( $\geq 5$ mm). Histopathology, 1998, 33, 406-413.	2.9	38
673	Correspondence. European Journal of Cancer, 1998, 34, 203-204.	2.8	8
674	Endothelin in Primate Pregnancy and an Experimental Preeclampsia-Like Syndrome. Hypertension in Pregnancy, 1998, 17, 227-240.	1.1	2
675	Variability of cutaneous lymphatic flow rates in melanoma patients. Melanoma Research, 1998, 8, 279-282.	1.2	26
676	Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.. Journal of Clinical Oncology, 1998, 16, 2906-2912.	1.6	240
677	Desmoplastic and desmoplastic neurotropic melanoma. Cancer, 1998, 83, 1128-1135.	4.1	2
678	Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Journal of Surgical Oncology, 1998, 14, 238-247.	1.4	3
679	Exclusive Lymphatic Drainage from a Melanoma on the Back to Intraabdominal Lymph Nodes. Clinical Nuclear Medicine, 1998, 23, 71-73.	1.3	22
680	Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer, 1998, 83, 1128-35.	4.1	42
681	Frequency and Duration of Remission After Isolated Limb Perfusion for Melanoma. Archives of Surgery, 1997, 132, 903.	2.2	102
682	Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Research, 1997, 7, 500-506.	1.2	57
683	Cutaneous melanoma in childhood: Incidence and prognosis. Australasian Journal of Dermatology, 1997, 38, S44-S48.	0.7	23
684	Evidence for Preeclampsia in a Baboon Pregnancy with Twins. Hypertension in Pregnancy, 1997, 16, 223-228.	1.1	8

#	ARTICLE	IF	CITATIONS
685	Patients' attitudes to xenotransplantation. Lancet, The, 1997, 349, 1031.	13.7	32
686	Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for hemodialysis access. American Journal of Surgery, 1997, 173, 280-283.	1.8	46
687	Intramedullary spinal cord metastasis from carcinoma of the lung: detection by positron emission tomography. European Journal of Cancer, 1997, 33, 508-509.	2.8	27
688	Contralateral groin node metastasis from lower limb melanoma. European Journal of Cancer, 1997, 33, 976-977.	2.8	23
689	Lymphatic mapping and selective lymphadenectomy for melanoma: not yet standard therapy. European Journal of Surgical Oncology, 1997, 23, 397-398.	1.0	22
690	GIANT INFILTRATING LIPOMA OF THE THIGH CAUSING SCIATICA. ANZ Journal of Surgery, 1997, 67, 225-226.	0.7	3
691	Latex allergy: an emerging clinical and occupational health problem. Anaesthesia, 1997, 52, 570-575.	3.8	24
692	Variation in cutaneous lymphatic flow rates. Annals of Surgical Oncology, 1997, 4, 279-280.	1.5	25
693	Latex allergy: An emerging health hazard for operating theatre staff. British Journal of Surgery, 1997, 84, 289-290.	0.3	1
694	Sentinel node biopsy. , 1997, 66, 270-272.		24
695	Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head and Neck, 1997, 19, 589-594.	2.0	101
696	Latex allergy: An emerging health hazard for operating theatre staff. British Journal of Surgery, 1997, 84, 289-290.	0.3	0
697	Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Surgery, 1996, 119, 112-114.	1.9	14
698	Surgical resection of pulmonary metastatic melanoma: A review of 83 thoracotomies. Heart, Lung and Circulation, 1996, 5, 111-114.	0.1	12
699	Retrieval of organs for transplantation: experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1996, 165, 375-378.	1.7	2
700	Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Research, 1996, 6, 325-330.	1.2	164
701	Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Research, 1996, 6, 267-271.	1.2	23
702	DELAYED RUPTURE OF THE SPLEEN 5 1/2 YEARS AFTER CONSERVATIVE MANAGEMENT OF TRAUMATIC SPLENIC INJURY. ANZ Journal of Surgery, 1996, 66, 494-495.	0.7	13

#	ARTICLE	IF	CITATIONS
703	MELANOMA OF THE LIP. ANZ Journal of Surgery, 1996, 66, 327-330.	0.7	13
704	Polypoid melanoma is not rare. British Journal of Dermatology, 1996, 135, 333-334.	1.5	7
705	Anaesthetic experience with isolated limb perfusion with melphalan for melanoma. Perfusion (United Kingdom), 1994, 9, 399-404.	1.0	1
706	The Role of Whole-Body Positron Emission Tomography With [18F]Fluorodeoxyglucose in Identifying Operable Colorectal Cancer Metastases to the Liver. Archives of Surgery, 1996, 131, 703.	2.2	216
707	Direct Lymphatic Drainage From the Skin of the Forearm to a Supraclavicular Node. Clinical Nuclear Medicine, 1996, 21, 387-389.	1.3	25
708	Lymphatic drainage to triangular intermuscular space lymph nodes in melanoma on the back. Journal of Nuclear Medicine, 1996, 37, 964-6.	5.0	53
709	Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Research, 1995, 5, 255-260.	1.2	430
710	Lymphatic Drainage From Peri-Umbilical Skin to Internal Mammary Nodes. Clinical Nuclear Medicine, 1995, 20, 254-255.	1.3	50
711	Obtaining Consent for Organ Donation in Nine NSW Metropolitan Hospitals. Anaesthesia and Intensive Care, 1995, 23, 81-87.	0.7	16
712	Can Cadaveric Organ Donation Rates be Improved?. Anaesthesia and Intensive Care, 1995, 23, 99-103.	0.7	10
713	The Identification of Potential Cadaveric Organ Donors. Anaesthesia and Intensive Care, 1995, 23, 75-80.	0.7	14
714	Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. American Journal of Surgery, 1995, 170, 461-466.	1.8	268
715	Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. Journal of the American College of Surgeons, 1995, 180, 402-9.	0.5	43
716	Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs. Perfusion (United Kingdom), 1994, 9, 399-404.	1.0	1
717	HAEMODYNAMIC ACTIONS OF A NITRIC OXIDE (EDRF) SYNTHESIS INHIBITOR IN CONSCIOUS BABOONS (Papio Tj ETQq1 1 0.784314 r	1.9	4
718	Noise pollution in the anaesthetic and intensive care environment. Anaesthesia, 1994, 49, 982-986.	3.8	104
719	EFFECTS OF TOTAL HEPATECTOMY: STUDIES IN A PORCINE MODEL. ANZ Journal of Surgery, 1994, 64, 560-564.	0.7	10
720	Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Research, 1994, 4, 395-399.	1.2	135

#	ARTICLE	IF	CITATIONS
721	Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Research, 1994, 4 Suppl 1, 45-50.	1.2	16
722	RIGHT CHYLOTHORAX FOLLOWING LEFT RADICAL NECK DISSECTION. ANZ Journal of Surgery, 1993, 63, 77-79.	0.7	9
723	UNILATERAL PIRIFORMIS SYNDROME IN A PATIENT WITH PREVIOUS MELANOMA. ANZ Journal of Surgery, 1993, 63, 152-153.	0.7	7
724	NAEVOID BASAL CELL CARCINOMA (GORLIN'S) SYNDROME. ANZ Journal of Surgery, 1993, 63, 413-415.	0.7	3
725	COMMON BILE DUCT OBSTRUCTION DUE TO INTRALUMINAL METASTATIC MELANOMA. ANZ Journal of Surgery, 1993, 63, 502-504.	0.7	15
726	OCULAR MELANOMA IN CHILDHOOD. ANZ Journal of Surgery, 1993, 63, 729-731.	0.7	7
727	Isolated limb perfusion with urokinase for acute ischemia. Journal of Vascular Surgery, 1993, 17, 408-413.	1.1	15
728	New route for metastatic spread of melanoma?. Lancet, The, 1993, 341, 302.	13.7	8
729	Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. Journal of Nuclear Medicine, 1993, 34, 1435-40.	5.0	152
730	The first five years' clinical experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1992, 156, 9-16.	1.7	18
731	Non-Subungual Melanomas of the Hand. Journal of Hand Surgery, 1992, 17, 433-436.	0.8	16
732	Malignant melanoma in childhood: A clinicopathologic study of 13 cases and comparison with spitz nevi. World Journal of Surgery, 1992, 16, 179-185.	1.6	65
733	Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World Journal of Surgery, 1992, 16, 227-233.	1.6	124
734	SURGICAL ONCOLOGY AND THE ROLE OF REGIONAL CHEMOTHERAPY. ANZ Journal of Surgery, 1992, 62, 691-696.	0.7	10
735	THE RATIONAL USE OF HOMOLOGOUS BLOOD IN ELECTIVE SURGERY. ANZ Journal of Surgery, 1992, 62, 266-269.	0.7	0
736	Donor factors and liver transplantation. Transplantation Proceedings, 1992, 24, 2083-4.	0.6	0
737	Can the demand for cadaver kidneys be met?. Transplantation Proceedings, 1992, 24, 2270-1.	0.6	1
738	Experience with 998 cutaneous melanomas of the head and neck over 30 years. American Journal of Surgery, 1991, 162, 310-314.	1.8	471

#	ARTICLE	IF	CITATIONS
739	Acute and subacute fulminant hepatic failure: the role of liver transplantation. Medical Journal of Australia, 1991, 154, 724-728.	1.7	27
740	A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: The use of monoclonal antibodies and double immunolabeling. Hepatology, 1990, 12, 1305-1313.	7.3	61
741	Hemodynamics of conscious unrestrained baboons, including cardiac output. Journal of Applied Physiology, 1990, 68, 2373-2379.	2.5	11
742	Aortic Occlusion and Vascular Isolation Allowing Avascular Hepatic Resection. Archives of Surgery, 1990, 125, 1482.	2.2	30
743	Noise pollution in the operating theatre. Lancet, The, 1990, 335, 891-894.	13.7	186
744	Thin regressing malignant melanoma: Significance of concurrent regional lymph node metastases. Histopathology, 1989, 15, 257-265.	2.9	67
745	CONTROL OF LIFE-THREATENING BLEEDING FROM CAPUT MEDUSAE BY UMBILICAL VEIN EMBOLISATION. Lancet, The, 1989, 333, 736.	13.7	11
746	DECISION-MAKING IN 100 PATIENTS REFERRED TO THE AUSTRALIAN NATIONAL LIVER TRANSPLANTATION UNIT. Australian and New Zealand Journal of Medicine, 1989, 19, 132-137.	0.5	4
747	CYCLOSPORIN CONVERSION VERSUS CONVENTIONAL IMMUNOSUPPRESSION: LONG-TERM FOLLOW-UP AND HISTOLOGICAL EVALUATION. Lancet, The, 1987, 329, 586-591.	13.7	68
748	Initial report of the Australian National Pilot Liver Transplantation Programme. Medical Journal of Australia, 1987, 147, 372-380.	1.7	16
749	The influence of HLA-A,B and -DR matching on leucocyte infiltration in renal allografts. Tissue Antigens, 1987, 29, 214-223.	1.0	4
750	Nonocclusive chronic vascular catheterization of conscious unrestrained baboons. Journal of Applied Physiology, 1986, 61, 1955-1958.	2.5	4
751	MORPHOMETRIC ANALYSIS OF CELLULAR INFILTRATION ASSESSED BY MONOCLONAL ANTIBODY LABELING IN SEQUENTIAL HUMAN RENAL ALLOGRAFT BIOPSIES. Transplantation, 1986, 42, 352-357.	1.0	126
752	The Problems Associated with Conversion from Azathioprine and Prednisolone to Cyclosporine. Uremia Investigation, 1985, 9, 19-25.	0.1	3
753	SKIN CANCER IN RENAL TRANSPLANT PATIENTS TREATED WITH CYCLOSPORIN. Lancet, The, 1985, 325, 158-159.	13.7	32
754	GOUT AND HYPERURICAEMIA IN PATIENTS ON CYCLOSPORIN AND DIURETICS. Lancet, The, 1985, 325, 453.	13.7	31
755	IS PREGRAFT BLOOD TRANSFUSION BENEFICIAL IN CYCLOSPORIN-TREATED RENAL TRANSPLANT RECIPIENTS?. Lancet, The, 1984, 323, 98.	13.7	8
756	CONTROL OF HYPERTENSION AFTER RENAL TRANSPLANTATION BY EMBOLISATION OF HOST KIDNEYS. Lancet, The, 1984, 324, 424-427.	13.7	15



#	ARTICLE	IF	CITATIONS
757	Surgery in Patients with Advanced Germ Cell Malignancy following a Clinical Partial Response to Chemotherapy. Journal of Urology, 1984, 131, 412-412.	0.4	0
758	Embolisation of host kidneys for the control of hypertension after renal transplantation: radiological aspects. British Journal of Radiology, 1984, 57, 279-284.	2.2	19
759	Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy. Journal of Surgical Oncology, 1983, 23, 223-227.	1.7	10
760	THE MANAGEMENT OF PANCREATIC CARCINOMA: A REVIEW OF 173 CASES. ANZ Journal of Surgery, 1983, 53, 25-30.	0.7	12
761	A CONTROLLED TRIAL OF CYCLOSPORINE IN RENAL TRANSPLANTATION WITH CONVERSION TO AZATHIOPRINE AND PREDNISOLONE AFTER THREE MONTHS. Transplantation, 1983, 36, 273-276.	1.0	91
762	Hypertrichosis and Multiple Cutaneous Squamous Cell Carcinomas in Association with Cyclosporin a Therapy. Journal of the Royal Society of Medicine, 1983, 76, 786-787.	2.0	21
763	Role of T-Cell-Subset Monitoring in Renal-Allograft Recipients. New England Journal of Medicine, 1982, 306, 1110-1111.	27.0	22
764	MONOCLONAL ANTIBODIES AND FINE NEEDLE ASPIRATION CYTOLOGY IN DETECTING RENAL ALLOGRAFT REJECTION. Lancet, The, 1982, 320, 278.	13.7	12
765	CYCLOSPORIN A IN OLIGURIC RENAL TRANSPLANT RECIPIENTS. Lancet, The, 1981, 318, 876.	13.7	2
766	LIVER RESECTION FOR NEOPLASM. ANZ Journal of Surgery, 1981, 51, 274-279.	0.7	5